Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
|Videos|May 12, 2021
Dr. Earle Burgess on the next steps with PARP inhibitors in prostate cancer
Author(s)Urology Times staff
Advertisement
Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, shares his expertise on what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), and other PARP agents are moving through the pipeline.
Advertisement
Related to this article
Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.
Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
5